[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336096-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336096-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mfolfirinox-versus-mfolfox-6-as-adjuvant-treatment-for-high-risk-stage-iii-colon-cancer-the-frost-trial-study-protocol-for-a-multicenter-randomized-controlled-phase-ii-trial","mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial","","High-risk stage III colon cancer carries a substantially worse prognosis than stage II and low-risk stage III disease, yet guidelines often rely on similar adjuvant strategies despite limited dedicated evidence and a need for improved outcomes. The FROST phase II multicenter trial evaluates whether mFOLFIRINOX improves oncologic efficacy and safety compared with standard mFOLFOX 6 after radical resection in patients with high-risk stage III colon cancer. Key outcomes include 3-year disease-free survival, with overall survival and toxicity as secondary endpoints.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mfolfirinox-versus-mfolfox-6-as-adjuvant-treatment-for-high-risk-stage-iii-colon-cancer-the-frost-trial-study-protocol-for-a-multicenter-randomized-controlled-phase-ii-trial/336096/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mfolfirinox-versus-mfolfox-6-as-adjuvant-treatment-for-high-risk-stage-iii-colon-cancer-the-frost-trial-study-protocol-for-a-multicenter-randomized-controlled-phase-ii-trial/336096.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the FROST trial address?","Question",{"text":63,"@type":64},"The trial compares the oncologic efficacy and safety of mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment after radical resection for high-risk stage III colon cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is the trial designed and how many patients are planned?",{"text":68,"@type":64},"It is a multicenter, randomized (1:1), open-label phase II trial aiming to enroll 312 eligible patients from 11 institutes.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the primary and secondary endpoints?",{"text":72,"@type":64},"The primary endpoint is 3-year disease-free survival. Secondary endpoints include 3-year overall survival and treatment toxicity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336096,1790150901,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":22,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Lee et al. BMC Cancer (2024) 24:397 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-11939-x](https://doi.org/10.1186/s12885-024-11939-x)  \nSTUDY PROTOCOL Open Access  \nmFOLFIRINOX versus mFOLFOX 6 as adjuvant  treatment for high-risk stage III colon  \ncancer-the FROST trial: study protocol for amulticenter, randomized controlled, phase II trial  \nKyung-Ha Lee 1, In Jun Yang 1, Gi Won Ha2, Jaeim Lee3, Youn Young Park4, Suk Hwan Lee4, Jong Min Lee5,  \nJung Hoon Bae6, Eun Jung Park7, Hyungjin Kim8, Keun Young Kim9, Sanghyung An 10, Ik Yong Kim 10 and Ji Yeon Kim 1*  \nAbstract  \nBackground High-risk stage III colon cancer has a considerably poorer prognosis than stage II and low-risk stage III colon cancers. Nevertheless, most guidelines recommend similar adjuvant treatment approaches for all these stages despite the dearth of research focusing on high-risk stage III colon cancer and the potential for improved prognosis with intensive adjuvant treatment. Given the the proven efficacy of triplet chemotherapy in metastatic colorectal cancer treatment, the goal of this study is to evaluate the oncologic efficacy and safety of mFOLFIRINOXin comparison to those of the current standard of care, mFOLFOX 6, as an adjuvant treatment for patients diagnosed with high-risk stage III colon cancer after radical resection.  \nMethods This multicenter, randomized (1:1), open-label, phase II trial will assess and compare the effectiveness and toxicity of mFOLFIRINOX and mFOLFOX 6 in patients with high-risk stage III colon cancer after radical resection. The goal of the trial is to enroll 312 eligible patients, from 11 institutes, aged between 20 and 70 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, or between 70 and 75 with an ECOG performance status of 0. Patients will be randomized into two arms-Arm A, the experimental arm, and Arm B, the reference armand will receive 12 cycles of mFOLFIRINOX and mFOLFOX 6 every 2 weeks, respectively. The primary endpoint of this study is the 3-year disease-free survival, and secondary endpoints include the 3-year overall survival and treatment toxicity.  \nDiscussion The Frost trial would help determine the oncologic efficacy and safety of adjuvant triplet chemotherapy for high-risk stage III colon cancers and ultimately improve prognoses.  \nTrial registration [ClinicalTrials.gov](ClinicalTrials.gov) NCT05179889, registered on 17 December 2021.  \n*Correspondence: Ji Yeon Kim [jkim@cnu.ac.kr](jkim@cnu.ac.kr)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nLee et al. BMC Cancer (2024) 24:397 Page 2 of 8  \nKeywords High-risk stage III colon cancer, Adjuvant chemotherapy, mFOLFIRINOX, mFOLFOX 6, Prognosis, Efficacy, Toxicity  \nBackground  \nBased on numerous studies conducted since the publication of the M","cbCaiiZAa5jVRPLc","https://ap.wps.com/l/cbCaiiZAa5jVRPLc","pdf",1081787,"English","# Background\n# Methods\n# Discussion\n# Trial registration\n# Keywords","[{\"question\":\"What question does the FROST trial address?\",\"answer\":\"The trial compares the oncologic efficacy and safety of mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment after radical resection for high-risk stage III colon cancer.\"},{\"question\":\"How is the trial designed and how many patients are planned?\",\"answer\":\"It is a multicenter, randomized (1:1), open-label phase II trial aiming to enroll 312 eligible patients from 11 institutes.\"},{\"question\":\"What are the primary and secondary endpoints?\",\"answer\":\"The primary endpoint is 3-year disease-free survival. Secondary endpoints include 3-year overall survival and treatment toxicity.\"}]","mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial | PDF",1790013573,[146],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/423549ad8fbffa89234d58d3f7d3626b.webp",983,1310]